FY24 results are broadly in line with the well flagged trading update. Revenue of £12.0m (SCMe £12.4m) and adj. EBITDA of £0.1m (SCMe £0.5m), with the latter primarily a consequence of NHS disruption in the UK. Given the challenging market however, it was positive to see sales growth across key segments and geographies (notably SI branded +7% in EU, APAC & RoW). With restructuring efforts now complete, new UK distribution agreements secured (Microline Surgical and Peters Surgical), and further o ....
